BioStock: BioInvent comments on the new chapter for BI-1206
RefinitivThời gian đọc: dưới 1 phút
BioInvent has launched a phase IIa clinical study of its antibody BI-1206 together with MSD’s Keytruda. The trial targets treatment-naive patients with advanced or metastatic non-small cell lung cancer and uveal melanoma – two cancers where new treatment options are urgently needed. We reached out to Dr. Andres McAllister, Chief Medical Officer at BioInvent, for a comment.
Read the full interview at biostock.se:
BioInvent comments on the next chapter for BI-1206
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Đăng nhập hoặc tạo tài khoản miễn phí trọn đời để đọc tin tức này